English

Elos Medtech Interim Report January 1 - March 31, 2022

Report this content

January – March 2022

  • Net sales for the first quarter amounted to SEK 194.5 (171.2) million, an increase of 13.6 percent compared to the same quarter last year. Net sales in local currencies increased by 7.6 percent.
  • Operating profit amounted to SEK 29.2 (25.0) million, corresponding to an operating margin of 15.0 (14.6) percent.
  • Profit after net financial items amounted to SEK 29.8 (27.1) million. Net financial items were positively affected by exchange rate differences of SEK 0.8 (2.8) million and totaled SEK 0.6 (2.1) million.
  • Profit after tax amounted to SEK 23.0 (20.0) million.
  • Cash flow from operating activities was SEK 8.3 (24.3) million, and SEK -20 (-11.5) million after investments.
  • Earnings per share amounted to SEK 2.85 (2.48).

For further information, please contact:
Jan Wahlström, President and CEO, +46 70-212 18 89, e-mail: jan.wahlstrom@elosmedtech.com
Ewa Linsäter, Group CFO, +46 76-633 32 33, e-mail: ewa.linsater@elosmedtech.com

This information is information that Elos Medtech AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on April 26, 2022, at 08:00 (CEST).

For additional information about the Elos Medtech Group, visit www.elosmedtech.com

Tags:

Interim report Medical Devices Elos Medtech

Subscribe

Documents & Links